| 摘要 |
PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition as a preventive/therapeutic agent for diseases due to collagen accumulation (e.g. hepatocirrhosis), containing, as active ingredient, a polynucleotide hybridizable with a specific base sequence in the genomic DNA of stress protein HSP47. SOLUTION: This pharmaceutical composition contains a polynucleotide hybridizable with a base sequence of the formula in the 1st intron in the genomic DNA in stress protein HSP47. It has been found that this composition plays as an important role in the coexpression of collagen, based on the fact that transcription activation ability cannot be seen in BS14 and BS18 among various defective variations in the 1st intron which has been proved to be supporting the coexpression of collagen as a result of luciferase assay in a promoter domain containing intron downstream of mouse genomic library. Therefore, by controlling the activity of 93bp of the formula containing both BS14 and BS18, collagen expression in collagen-productive cells can be controlled. |
